Built-in Effort Tracking Streamlines Resource Allocation and Budgeting for Users of Allegro CTMS@Site
The summer release of Allegro [email protected]®, from Forte Research Systems, Inc., is full of new features that allow sites to operate more dynamically and efficiently. The clinical trial management system has new calendar options for managing staff time and expanded report choices. In addition, the summer release includes the feature of staff effort tracking.
The new functionality in Allegro [email protected] can help solve the problem of underestimating the number of hours staff spends on activities by allowing the site to track the staff time involved on any number of clinical trials, based on user-defined categories. Additionally, the staff management calendar feature grants selected site staff the opportunity to view schedules of other staff members from within the CTMS.
To set up a demonstration of Allegro [email protected] or to learn more, please contact Forte Research Systems.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
